Who
Mark L. Jacobson
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Axsome Therapeutics.
In numbers
- Trades disclosed
- 71
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $37.7M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 17 Mar 2020
- Last trade
- 3 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 3 Sep 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $130K10,000 at $12.95 | filing |
| 3 Sep 2026filed 3 Sep 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.1M10,000 at $208.65 | filing |
| 3 Sep 2026filed 3 Sep 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 3 Sep 2026filed 3 Sep 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 3 Sep 2026filed 3 Sep 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $130K10,000 at $12.95 | filing |
| 3 Sep 2026filed 3 Sep 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.1M10,000 at $208.65 | filing |
| 5 May 2026filed 5 May 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $3,017233 at $12.95 | filing |
| 5 May 2026filed 5 May 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —233 at $0.00 | filing |
| 5 May 2026filed 5 May 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $53K233 at $228.18 | filing |
| 5 May 2026filed 5 May 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —233 at $0.00 | filing |
| 5 May 2026filed 5 May 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $3,017233 at $12.95 | filing |
| 5 May 2026filed 5 May 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $53K233 at $228.18 | filing |
| 4 May 2026filed 5 May 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $58K4,517 at $12.95 | filing |
| 4 May 2026filed 5 May 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M4,517 at $227.94 | filing |
| 4 May 2026filed 5 May 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,517 at $0.00 | filing |
| 4 May 2026filed 5 May 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,517 at $0.00 | filing |
| 4 May 2026filed 5 May 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $58K4,517 at $12.95 | filing |
| 4 May 2026filed 5 May 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M4,517 at $227.94 | filing |
| 21 Apr 2026filed 23 Apr 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,669 at $0.00 | filing |
| 21 Apr 2026filed 23 Apr 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,669 at $0.00 | filing |
News
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?AXSM · insidermonkey.com · 13 Oct 2026Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?AXSM · fool.com · 12 Oct 2026
0 headlines in the last 90 days name Mark L. Jacobson; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.